Q2 2019 EPS Estimates for Tcr2 Therapeutics Inc (TCRR) Cut by Svb Leerink
Tcr2 Therapeutics Inc (NASDAQ:TCRR) – Stock analysts at Svb Leerink lowered their Q2 2019 earnings estimates for Tcr2 Therapeutics in a research report issued on Monday, May 13th. Svb Leerink analyst J. Chang now forecasts that the company will post earnings of ($0.51) per share for the quarter, down from their prior forecast of ($0.47). Svb Leerink has a “Outperform” rating and a $27.00 price objective on the stock. Svb Leerink also issued estimates for Tcr2 Therapeutics’ Q3 2019 earnings at ($0.55) EPS, Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($4.75) EPS and FY2020 earnings at ($2.92) EPS.
Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings data on Monday, May 13th. The company reported ($4.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($4.47).
Shares of Tcr2 Therapeutics stock opened at $15.62 on Thursday. Tcr2 Therapeutics has a 1 year low of $13.87 and a 1 year high of $25.47. The firm has a market cap of $373.94 million and a P/E ratio of -0.16.
Large investors have recently modified their holdings of the stock. Dean Capital Investments Management LLC acquired a new stake in Tcr2 Therapeutics during the 1st quarter worth $694,000. Parametric Portfolio Associates LLC purchased a new position in shares of Tcr2 Therapeutics in the 1st quarter valued at about $495,000. Oxford Asset Management LLP purchased a new position in shares of Tcr2 Therapeutics in the 1st quarter valued at about $301,000. Citigroup Inc. purchased a new position in Tcr2 Therapeutics during the 1st quarter valued at about $39,000. Finally, BlueCrest Capital Management Ltd purchased a new position in Tcr2 Therapeutics during the 1st quarter valued at about $458,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.
In other news, Director Morana Jovan-Embiricos acquired 666,667 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were bought at an average cost of $15.00 per share, with a total value of $10,000,005.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Upnorth Investment Ltd acquired 200,000 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Recommended Story: Cost of Capital
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.